Trial · NCT00759720
Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.
NCT00759720, Phase 3, Terminated, Takeda
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus. Trials, record NCT00759720. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00759720
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of TAK-559 Combined With Glyburide in Treating Subjects With Type 2 Diabetes Mellitus.
- NCT number
- NCT00759720
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 447 participants, actual
- Lead sponsor
- Takeda
- Conditions
- Diabetes Mellitus
- Interventions
- TAK-559 and glyburide, TAK-559 and glyburide, Glyburide
- First posted
- 2008-09-25
- Last updated
- 2012-02-02
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Glycosylated hemoglobin level. | Final Visit | |
| Secondary | Change from baseline in Glycosylated hemoglobin level. | Weeks: 4, 8, 12, 16 and 20. | |
| Secondary | Change from baseline in Fasting plasma glucose. | At all Visits. | |
| Secondary | Change from Baseline in Serum insulin. | Weeks: 4, 12, 16, 20 and Final Visit. | |
| Secondary | Change from Baseline in C-peptide. | Weeks: 4, 12, 16, 20 and Final Visit. | |
| Secondary | Change from Baseline in Lipids (triglyceride, total cholesterol, high-density lipoprotein, low-density lipoprotein and very low-density lipoproteins) | Weeks: 12, 16, 20 and Final Visit. | |
| Secondary | Change from Baseline in Apolipoproteins [A1 and B]). | Final Visit | |
| Secondary | Change from Baseline in Free fatty acids. | Weeks: 12, 16, 20 and Final Visit. | |
| Secondary | Markers of thrombosis (plasminogen activator inhibitor-1 and fibrinogen). | Weeks: 4, 12, 16, 20 and Final Visit. | |
| Secondary | Markers of inflammation (interleukin-6 and C-reactive protein). | Weeks: 4, 12, 16, 20 and Final Visit. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00759720
GET https://conductscience.org/api/trials/v1/NCT00759720/registered